139 related articles for article (PubMed ID: 30057142)
1. Targeting Myosin by Blebbistatin Derivatives: Optimization and Pharmacological Potential.
Rauscher AÁ; Gyimesi M; Kovács M; Málnási-Csizmadia A
Trends Biochem Sci; 2018 Sep; 43(9):700-713. PubMed ID: 30057142
[TBL] [Abstract][Full Text] [Related]
2. Improved Inhibitory and Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) Properties of Blebbistatin Derivatives Indicate That Blebbistatin Scaffold Is Ideal for drug Development Targeting Myosin-2.
Gyimesi M; Rauscher AÁ; Suthar SK; Hamow KÁ; Oravecz K; Lőrincz I; Borhegyi Z; Déri MT; Kiss ÁF; Monostory K; Szabó PT; Nag S; Tomasic I; Krans J; Tierney PJ; Kovács M; Kornya L; Málnási-Csizmadia A
J Pharmacol Exp Ther; 2021 Mar; 376(3):358-373. PubMed ID: 33468641
[TBL] [Abstract][Full Text] [Related]
3. Specificity of blebbistatin, an inhibitor of myosin II.
Limouze J; Straight AF; Mitchison T; Sellers JR
J Muscle Res Cell Motil; 2004; 25(4-5):337-41. PubMed ID: 15548862
[TBL] [Abstract][Full Text] [Related]
4. The small molecule tool (S)-(-)-blebbistatin: novel insights of relevance to myosin inhibitor design.
Lucas-Lopez C; Allingham JS; Lebl T; Lawson CP; Brenk R; Sellers JR; Rayment I; Westwood NJ
Org Biomol Chem; 2008 Jun; 6(12):2076-84. PubMed ID: 18528569
[TBL] [Abstract][Full Text] [Related]
5. Blebbistatin, a myosin inhibitor, is phototoxic to human cancer cells under exposure to blue light.
Mikulich A; Kavaliauskiene S; Juzenas P
Biochim Biophys Acta; 2012 Jul; 1820(7):870-7. PubMed ID: 22507270
[TBL] [Abstract][Full Text] [Related]
6. A highly soluble, non-phototoxic, non-fluorescent blebbistatin derivative.
Várkuti BH; Képiró M; Horváth IÁ; Végner L; Ráti S; Zsigmond Á; Hegyi G; Lenkei Z; Varga M; Málnási-Csizmadia A
Sci Rep; 2016 May; 6():26141. PubMed ID: 27241904
[TBL] [Abstract][Full Text] [Related]
7. Azidoblebbistatin, a photoreactive myosin inhibitor.
Képiró M; Várkuti BH; Bodor A; Hegyi G; Drahos L; Kovács M; Málnási-Csizmadia A
Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9402-7. PubMed ID: 22647605
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Blebbistatin Inhibition of Smooth Muscle Myosin and Nonmuscle Myosin-2.
Zhang HM; Ji HH; Ni T; Ma RN; Wang A; Li XD
Biochemistry; 2017 Aug; 56(32):4235-4243. PubMed ID: 28714309
[TBL] [Abstract][Full Text] [Related]
9. Drug specificity and affinity are encoded in the probability of cryptic pocket opening in myosin motor domains.
Meller A; Lotthammer JM; Smith LG; Novak B; Lee LA; Kuhn CC; Greenberg L; Leinwand LA; Greenberg MJ; Bowman GR
Elife; 2023 Jan; 12():. PubMed ID: 36705568
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo relaxation of urinary bladder smooth muscle by the selective myosin II inhibitor, blebbistatin.
Zhang X; Kuppam DS; Melman A; DiSanto ME
BJU Int; 2011 Jan; 107(2):310-7. PubMed ID: 20482706
[TBL] [Abstract][Full Text] [Related]
11. Blebbistatin, a myosin II inhibitor, is photoinactivated by blue light.
Sakamoto T; Limouze J; Combs CA; Straight AF; Sellers JR
Biochemistry; 2005 Jan; 44(2):584-8. PubMed ID: 15641783
[TBL] [Abstract][Full Text] [Related]
12. Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
Roman BI; Verhasselt S; Stevens CV
J Med Chem; 2018 Nov; 61(21):9410-9428. PubMed ID: 29878759
[TBL] [Abstract][Full Text] [Related]
13. para-Nitroblebbistatin, the non-cytotoxic and photostable myosin II inhibitor.
Képiró M; Várkuti BH; Végner L; Vörös G; Hegyi G; Varga M; Málnási-Csizmadia A
Angew Chem Int Ed Engl; 2014 Jul; 53(31):8211-5. PubMed ID: 24954740
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of C-ring-modified blebbistatin derivatives and evaluation of their myosin II ATPase inhibitory potency.
Roman BI; Verhasselt S; Mangodt CW; De Wever O; Stevens CV
Bioorg Med Chem Lett; 2018 Jul; 28(13):2261-2264. PubMed ID: 29807794
[TBL] [Abstract][Full Text] [Related]
15. Discovery of (S)-3'-hydroxyblebbistatin and (S)-3'-aminoblebbistatin: polar myosin II inhibitors with superior research tool properties.
Verhasselt S; Roman BI; De Wever O; Van Hecke K; Van Deun R; Bracke ME; Stevens CV
Org Biomol Chem; 2017 Mar; 15(9):2104-2118. PubMed ID: 28220174
[TBL] [Abstract][Full Text] [Related]
16. Phototoxicity and photoinactivation of blebbistatin in UV and visible light.
Kolega J
Biochem Biophys Res Commun; 2004 Jul; 320(3):1020-5. PubMed ID: 15240150
[TBL] [Abstract][Full Text] [Related]
17. Insights into the myosin II inhibitory potency of A-ring-modified (S)-blebbistatin analogs.
Verhasselt S; Stevens CV; Van den Broecke T; Bracke ME; Roman BI
Bioorg Med Chem Lett; 2017 Jul; 27(13):2986-2989. PubMed ID: 28512027
[TBL] [Abstract][Full Text] [Related]
18. Potent inhibition of arterial smooth muscle tonic contractions by the selective myosin II inhibitor, blebbistatin.
Eddinger TJ; Meer DP; Miner AS; Meehl J; Rovner AS; Ratz PH
J Pharmacol Exp Ther; 2007 Feb; 320(2):865-70. PubMed ID: 17132816
[TBL] [Abstract][Full Text] [Related]
19. Kinetic mechanism of blebbistatin inhibition of nonmuscle myosin IIb.
Ramamurthy B; Yengo CM; Straight AF; Mitchison TJ; Sweeney HL
Biochemistry; 2004 Nov; 43(46):14832-9. PubMed ID: 15544354
[TBL] [Abstract][Full Text] [Related]
20. The myosin II ATPase inhibitor blebbistatin prevents thrombin-induced inhibition of intercellular calcium wave propagation in corneal endothelial cells.
Ponsaerts R; D'hondt C; Bultynck G; Srinivas SP; Vereecke J; Himpens B
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4816-27. PubMed ID: 18614806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
